At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
Ivermectin +1 moredrug
Likely dose
Ivermectin 400mcg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission
Clinica Universidad de Navarra, Universidad de Navarra·interventional·Posted May 15, 2020·Updated Dec 17, 2020
In Brief
A Phase 2 clinical trial evaluating Ivermectin and Placebo for Covid-19 and 2 related conditions. Completed, enrolled 24 participants across 1 site.
Detailed Summary
SAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in SARS-CoV-2 infected patients who are at low risk of progression to severe disease. The trial is currently planned at a single center in Navarra.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid-19, Coronavirus Infection, SARS-CoV-2 Infection
CountriesSpain
CollaboratorsBarcelona Institute for Global Health
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartJul 2020
Primary CompletionSep 2020
Study CompletionOct 2020
TodayJul 2026
First PostedMay 15, 2020
Enrollment StartJul 31, 2020
Primary CompletionSep 17, 2020
Study CompletionOct 9, 2020
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 6.1 years ago
Interventions
Ivermectindrug
Single dose of STROMECTOL® tablets at 400mcg/kg
Placebodrug
Placebo tablets will not match ivermectin but they will be administered by staff not involved in the clinical care.